These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34995958)

  • 1. Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy.
    Haque A; Pant AB
    J Autoimmun; 2022 Feb; 127():102792. PubMed ID: 34995958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
    Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
    Jacob JJ; John Fletcher G; Monisha Priya T; Veeraraghavan B; Mutreja A
    Indian J Med Microbiol; 2021; 39(4):417-422. PubMed ID: 34454775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omicron: Call for updated vaccines.
    Li X
    J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long road.
    Cohen J
    Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
    [No Abstract]   [Full Text] [Related]  

  • 10. A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.
    Zhang M; Liang Y; Yu D; Du B; Cheng W; Li L; Yu Z; Luo S; Zhang Y; Wang H; Zhang X; Zhang W
    Int J Biol Sci; 2022; 18(2):889-900. PubMed ID: 35002532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy.
    Ameratunga R
    Expert Rev Vaccines; 2022 Sep; 21(9):1177-1184. PubMed ID: 35695410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
    Burckhardt RM; Dennehy JJ; Poon LLM; Saif LJ; Enquist LW
    J Virol; 2022 Feb; 96(3):e0197321. PubMed ID: 34817198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
    Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
    Front Immunol; 2021; 12():809244. PubMed ID: 35046961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Vaccine Breakthrough by Omicron and Delta Variants, New York, USA.
    Keyel AC; Russell A; Plitnick J; Rowlands JV; Lamson DM; Rosenberg E; St George K
    Emerg Infect Dis; 2022 Oct; 28(10):1990-1998. PubMed ID: 36048774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
    Kantarcioglu B; Iqbal O; Lewis J; Carter CA; Singh M; Lievano F; Ligocki M; Jeske W; Adiguzel C; Gerotziafas GT; Fareed J
    Clin Appl Thromb Hemost; 2022; 28():10760296211056648. PubMed ID: 35167393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.
    Wang CY; Hwang KP; Kuo HK; Peng WJ; Shen YH; Kuo BS; Huang JH; Liu H; Ho YH; Lin F; Ding S; Liu Z; Wu HT; Huang CT; Lee YJ; Liu MC; Yang YC; Lu PL; Tsai HC; Lee CH; Shi ZY; Liu CE; Liao CH; Chang FY; Chen HC; Wang FD; Hou KL; Cheng J; Wang MS; Yang YT; Chiu HC; Jiang MH; Shih HY; Shen HY; Chang PY; Lan YR; Chen CT; Lin YL; Liang JJ; Liao CC; Chou YC; Morris MK; Hanson CV; Guirakhoo F; Hellerstein M; Yu HJ; King CC; Kemp T; Heppner DG; Monath TP
    J Clin Invest; 2022 May; 132(10):. PubMed ID: 35316221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.